NanoViricides, Inc. (NYSE American: NNVC) announced it has submitted an application to the Democratic Republic of Congo’s regulatory agency seeking approval to initiate a Phase II clinical trial evaluating its NV-387 Oral Gummies as a treatment for the current Bundibugyo ebolavirus outbreak. The company has retained Om Sai Clinical Research Private Limited as the contract research organization for the study, with drug supplies already positioned in the DRC. NV-387 is an orally administered broad-spectrum antiviral designed to target host-side mechanisms that viruses rely on to infect cells, a strategy the company believes may reduce the likelihood of viral resistance.
The planned study builds on NanoViricides’ ongoing Phase II Mpox trial in the DRC and comes as the company responds to an outbreak that, according to the release, has resulted in more than 930 deaths and nearly 2,400 confirmed cases since May. The company stated that NV-387’s oral formulation could offer logistical advantages over infusion-based therapies in resource-limited settings and, if successful, could support development of a broad-spectrum treatment for Ebola and other filoviruses. For further details, the full press release is available at https://ibn.fm/tmrCX.
NanoViricides is a clinical stage company creating special purpose nanomaterials for antiviral therapy. The company’s nanoviricide class of drug candidates and technology are based on intellectual property and proprietary know-how of TheraCour Pharma, Inc. Its lead drug candidate, NV-387, is being developed as a broad-spectrum antiviral for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox and Measles. The company also has other advanced candidates, including NV-HHV-1 for Shingles.
The significance of this application lies in the potential to provide an oral treatment option for Ebola, which could be more accessible in remote areas compared to intravenous therapies. If approved and successful, NV-387 could become a critical tool in managing outbreaks in regions with limited healthcare infrastructure. However, as with all drug development, there is no assurance that NV-387 will demonstrate sufficient safety and efficacy in human trials. More information about NanoViricides can be found at https://www.nanoviricides.com.
